$2.6 million secured to build APAS Revolution benchtop system
Clever Culture Systems Ltd (ASX: CC5) has secured commitments for a $2.6 million funding package (before costs) to develop APAS Revolution, a new benchtop configuration of the Automated Plate Assessment System. The package comprises a targeted $1.0 million capital raise and a $1.6 million unsecured loan.
APAS Revolution is designed to target smaller sterile drug manufacturing facilities not served by existing automation. The company said it expands the estimated total addressable market (TAM) for APAS technology by approximately 50%, from $2.8 billion to $4.3 billion.
Brent Barnes, CEO and Managing Director
“This is a measured investment with meaningful strategic potential: a complementary product, a significantly larger addressable market and a pathway to deeper relationships with pharmaceutical customers.”
Key highlights from the announcement:
- Commitments received for a $2.6 million funding package (before costs) for APAS Revolution product development
- Estimated TAM expanded by approximately 50% to $4.3 billion
- Clear growth opportunity alongside continued APAS Independence sales, expected to deliver payback in under 2 years from product launch
- The $1.6 million unsecured loan is due for repayment on 30 November 2027
When big ASX news breaks, our subscribers know first
Why APAS Revolution expands the market to $4.3 billion
Smaller sites, same proven technology
APAS Revolution will leverage the APAS imaging station, plate-gripping system and validated analysis modules (AI-powered algorithms) used on the commercially released APAS Independence instrument. The company describes it as an extension of an existing system rather than an entirely new platform.
According to the company, adapting this core technology lowers the cost of development, reduces the development timeline and lowers the development risk.
Sizing the opportunity
The company estimates a TAM exceeding 3,400 APAS Revolution instruments in addition to the 2,300 APAS Independence instruments.
| Platform | Estimated instruments | Target site |
|---|---|---|
| APAS Independence | 2,300 | Largest global manufacturing sites |
| APAS Revolution | 3,400 | Small to medium size, lower volume sterile drug manufacturing facilities |
The $4.3 billion figure includes the standard instrument price and annual fees for software licences and maintenance services over an expected 7-year instrument life. It is based on internal Company market research and an assumed USD:AUD exchange rate of 1.4.
What automated environmental monitoring means
Environmental monitoring plates are culture plates used in pharmaceutical manufacturing to check for microbial contamination in production environments. APAS technology uses artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of these plates.
The company says automation delivers quality, traceability and efficiency benefits. Lower-volume facilities require those benefits but do not require the processing capacity of APAS Independence, which is the gap APAS Revolution is designed to fill.
The company states the technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading.
Existing customers and PSC Biotech
The company anticipates that existing global pharmaceutical customers will provide a natural initial market opportunity, with the potential for a more rapid payback on development costs. The new system is intended to let these customers deploy a consistent APAS technology platform across large, medium and small manufacturing facilities.
PSC Biotech was recently appointed as a sales agent for APAS Independence in North America, Canada and Singapore. The company says its presence in pharmaceutical validation, engineering and regulatory services provides an additional channel to engage single-site and medium-sized operators, the target segment for APAS Revolution.
The PSC Biotech sales agreement gives Clever Culture exclusive US, Canada and Singapore coverage for APAS Independence, with PSC earning commission on hardware sales only while the company retains pricing and recurring software revenue.
Funding structure: placement and loan terms
The package combines equity from a placement with an unsecured loan, each with attached unlisted options.
Placement (equity)
| Item | Detail |
|---|---|
| Amount raised (before costs) | $1,000,000 |
| New Shares | 62,500,000 fully paid ordinary shares at $0.016 each |
| Discount to last traded price | 15.8% to $0.019 on 29 October 2026 |
| Discount to 15-trading day VWAP | 15.4% to $0.0189 |
| Attaching options | One unlisted option per New Share (62,500,000), exercise price $0.03, expiry 30 November 2029 |
| Joint Lead Managers | Blue Ocean Equities and Taylor Collison Ltd |
| Issuance capacity | Shares under ASX Listing Rule 7.1A; options under Listing Rule 7.1 |
Proceeds of the placement will be used to accelerate the development program for APAS Revolution. Firm commitments were received from sophisticated and professional investors.
Loan agreement (debt)
| Item | Detail |
|---|---|
| Loan amount | $1.6 million, unsecured |
| Interest | 10% per annum, interest only payments due quarterly |
| Repayment | Due 30 November 2027 |
| Loan options | 19,200,000 unlisted options (12 for every $1 in debt), exercise price $0.03, expiry 30 November 2029 |
| Broker remuneration | A further 9,600,000 options on the same terms |
| Total unlisted options | 28,800,000, under ASX Listing Rule 7.1 |
In the short term, the debt assists in retiring the existing $1.7 million short term loan due for repayment on 31 December 2026. The company also considers continued use of debt a capital efficient method of funding near-term working capital requirements, including the timing of customer receipts and inventory purchasing.
What happens next for APAS Revolution
The announcement sets out the following timeline:
- Monday, 9 November 2026: Placement settlement is expected to occur.
- Tuesday 10 November 2026: New Shares issued under the placement commence trading.
- By 30 November 2026: Loan funds are to be received.
- 31 December 2026: The existing $1.7 million short term loan is due for repayment.
- By 4 December 2026: The 28,800,000 unlisted options are anticipated to be issued.
- Soon to be selected: The external engineering partner for the product development project.
- 2027 calendar year: Pre-production instruments are expected to be released to customers for evaluation and final user feedback.
- 30 November 2027: The new loan is due for repayment.
- First half of the 2028 calendar year: Final product launch is expected.
The company says the combination of the capital raise and loan facility provides a capital light approach to product development. APAS Revolution is positioned as a complementary growth opportunity alongside continued APAS Independence sales, which the company expects to deliver payback in under 2 years from product launch.
Q1 FY27 APAS sales to Novo and AstraZeneca, together with an 8-unit half-year target, show the existing Independence business that the company expects to run alongside the Revolution development program.
Ready to Explore the APAS Revolution Opportunity?
Clever Culture Systems is moving to develop APAS Revolution, a benchtop system that expands its estimated addressable market by approximately 50% to $4.3 billion. Backed by a $2.6 million funding package, the project targets smaller sterile drug manufacturing facilities not served by existing automation.
Investors seeking more detail on the product roadmap, funding terms and growth strategy can visit the Clever Culture Systems investor centre. Explore the latest company updates to see how APAS Revolution could complement continued APAS Independence sales.